126 related articles for article (PubMed ID: 26609109)
21. Detailed analysis of five mutations in dihydropyrimidine dehydrogenase detected in cancer patients with 5-fluorouracil-related side effects.
Gross E; Ullrich T; Seck K; Mueller V; de Wit M; von Schilling C; Meindl A; Schmitt M; Kiechle M
Hum Mutat; 2003 Dec; 22(6):498. PubMed ID: 14635116
[TBL] [Abstract][Full Text] [Related]
22. Clinical implications of dihydropyrimidine dehydrogenase (DPD) activity in 5-FU-based chemotherapy: mutations in the DPD gene, and DPD inhibitory fluoropyrimidines.
Omura K
Int J Clin Oncol; 2003 Jun; 8(3):132-8. PubMed ID: 12851836
[TBL] [Abstract][Full Text] [Related]
23. Identification of three novel mutations in the dihydropyrimidine dehydrogenase gene associated with altered pre-mRNA splicing or protein function.
Van Kuilenburg AB; Meinsma R; Beke E; Bobba B; Boffi P; Enns GM; Witt DR; Dobritzsch D
Biol Chem; 2005 Apr; 386(4):319-24. PubMed ID: 15899693
[TBL] [Abstract][Full Text] [Related]
24. Diagnosis of dihydropyrimidine dehydrogenase deficiency in a neonate with thymine-uraciluria.
Au KM; Lai CK; Yuen YP; Shek CC; Lam CW; Chan AY
Hong Kong Med J; 2003 Apr; 9(2):130-2. PubMed ID: 12668826
[TBL] [Abstract][Full Text] [Related]
25. Insights into the mechanism of dihydropyrimidine dehydrogenase from site-directed mutagenesis targeting the active site loop and redox cofactor coordination.
Lohkamp B; Voevodskaya N; Lindqvist Y; Dobritzsch D
Biochim Biophys Acta; 2010 Dec; 1804(12):2198-206. PubMed ID: 20831907
[TBL] [Abstract][Full Text] [Related]
26. Dihydropyrimidine accumulation is required for the epithelial-mesenchymal transition.
Shaul YD; Freinkman E; Comb WC; Cantor JR; Tam WL; Thiru P; Kim D; Kanarek N; Pacold ME; Chen WW; Bierie B; Possemato R; Reinhardt F; Weinberg RA; Yaffe MB; Sabatini DM
Cell; 2014 Aug; 158(5):1094-1109. PubMed ID: 25171410
[TBL] [Abstract][Full Text] [Related]
27. Endogenous plasma and salivary uracil to dihydrouracil ratios and DPYD genotyping as predictors of severe fluoropyrimidine toxicity in patients with gastrointestinal malignancies.
Galarza AF; Linden R; Antunes MV; Hahn RZ; Raymundo S; da Silva AC; Staggemeier R; Spilki FR; Schwartsmann G
Clin Biochem; 2016 Nov; 49(16-17):1221-1226. PubMed ID: 27399164
[TBL] [Abstract][Full Text] [Related]
28. [Review of methods for determination of dihydropyrimidine dehydrogenase and possible application in screening previous chemotheraphy with 5-fluorouracil].
Ostapowicz A; Dołegowska B
Przegl Lek; 2012; 69(9):694-7. PubMed ID: 23401991
[TBL] [Abstract][Full Text] [Related]
29. DPYD*2A mutation: the most common mutation associated with DPD deficiency.
Saif MW; Ezzeldin H; Vance K; Sellers S; Diasio RB
Cancer Chemother Pharmacol; 2007 Sep; 60(4):503-7. PubMed ID: 17165084
[TBL] [Abstract][Full Text] [Related]
30. [The association between DPYD gene polymorphism and chemotherapeutic toxicity of 5-FU in gastric carcinoma and colonic carcinoma].
Zhang H; Li YM; Yu CH; Wang SQ; Ji F; Chen CX
Zhonghua Nei Ke Za Zhi; 2007 Feb; 46(2):103-6. PubMed ID: 17445431
[TBL] [Abstract][Full Text] [Related]
31. Potential of dihydropyrimidine dehydrogenase genotypes in personalizing 5-fluorouracil therapy among colorectal cancer patients.
Teh LK; Hamzah S; Hashim H; Bannur Z; Zakaria ZA; Hasbullani Z; Shia JK; Fijeraid H; Md Nor A; Zailani M; Ramasamy P; Ngow H; Sood S; Salleh MZ
Ther Drug Monit; 2013 Oct; 35(5):624-30. PubMed ID: 23942539
[TBL] [Abstract][Full Text] [Related]
32. Aberrant methylation of DPYD promoter, DPYD expression, and cellular sensitivity to 5-fluorouracil in cancer cells.
Noguchi T; Tanimoto K; Shimokuni T; Ukon K; Tsujimoto H; Fukushima M; Noguchi T; Kawahara K; Hiyama K; Nishiyama M
Clin Cancer Res; 2004 Oct; 10(20):7100-7. PubMed ID: 15501990
[TBL] [Abstract][Full Text] [Related]
33. Genotyping of a family with a novel deleterious DPYD mutation supports the pretherapeutic screening of DPD deficiency with dihydrouracil/uracil ratio.
Thomas F; Hennebelle I; Delmas C; Lochon I; Dhelens C; Garnier Tixidre C; Bonadona A; Penel N; Goncalves A; Delord JP; Toulas C; Chatelut E
Clin Pharmacol Ther; 2016 Feb; 99(2):235-42. PubMed ID: 26265035
[TBL] [Abstract][Full Text] [Related]
34. The role of Sp1 and Sp3 in the constitutive DPYD gene expression.
Zhang X; Li L; Fourie J; Davie JR; Guarcello V; Diasio RB
Biochim Biophys Acta; 2006 May; 1759(5):247-56. PubMed ID: 16806531
[TBL] [Abstract][Full Text] [Related]
35. Suppression of DPYD expression in RKO cells via DNA methylation in the regulatory region of the DPYD promoter: a potentially important epigenetic mechanism regulating DPYD expression.
Zhang X; Soong R; Wang K; Li L; Davie JR; Guarcello V; Diasio RB
Biochem Cell Biol; 2007 Jun; 85(3):337-46. PubMed ID: 17612628
[TBL] [Abstract][Full Text] [Related]
36. Chromosome 1p21.3 microdeletions comprising DPYD and MIR137 are associated with intellectual disability.
Willemsen MH; Vallès A; Kirkels LA; Mastebroek M; Olde Loohuis N; Kos A; Wissink-Lindhout WM; de Brouwer AP; Nillesen WM; Pfundt R; Holder-Espinasse M; Vallée L; Andrieux J; Coppens-Hofman MC; Rensen H; Hamel BC; van Bokhoven H; Aschrafi A; Kleefstra T
J Med Genet; 2011 Dec; 48(12):810-8. PubMed ID: 22003227
[TBL] [Abstract][Full Text] [Related]
37. A high-throughput denaturing high-performance liquid chromatography method for the identification of variant alleles associated with dihydropyrimidine dehydrogenase deficiency.
Ezzeldin H; Okamoto Y; Johnson MR; Diasio RB
Anal Biochem; 2002 Jul; 306(1):63-73. PubMed ID: 12069415
[TBL] [Abstract][Full Text] [Related]
38. Characterization of the human dihydropyrimidine dehydrogenase gene.
Wei X; Elizondo G; Sapone A; McLeod HL; Raunio H; Fernandez-Salguero P; Gonzalez FJ
Genomics; 1998 Aug; 51(3):391-400. PubMed ID: 9721209
[TBL] [Abstract][Full Text] [Related]
39. Novel somatic KIT exon 8 mutation with dramatic response to imatinib in a patient with mucosal melanoma: a case report.
Rapisuwon S; Parks K; Al-Refaie W; Atkins MB
Melanoma Res; 2014 Oct; 24(5):509-11. PubMed ID: 25003536
[TBL] [Abstract][Full Text] [Related]
40. Dihydropyrimidine dehydrogenase (DPD) expression is negatively regulated by certain microRNAs in human lung tissues.
Hirota T; Date Y; Nishibatake Y; Takane H; Fukuoka Y; Taniguchi Y; Burioka N; Shimizu E; Nakamura H; Otsubo K; Ieiri I
Lung Cancer; 2012 Jul; 77(1):16-23. PubMed ID: 22306127
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
